Eli Lilly And Co (NYSE:LLY) Holdings Lowered by Country Club Trust Company n.a.

Country Club Trust Company n.a. cut its position in Eli Lilly And Co (NYSE:LLY) by 14.1% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 2,133 shares of the company’s stock after selling 350 shares during the period. Country Club Trust Company n.a.’s holdings in Eli Lilly And Co were worth $277,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Bank of New York Mellon Corp grew its position in shares of Eli Lilly And Co by 0.3% in the third quarter. Bank of New York Mellon Corp now owns 9,501,142 shares of the company’s stock valued at $1,019,568,000 after purchasing an additional 27,009 shares during the last quarter. LPL Financial LLC grew its position in shares of Eli Lilly And Co by 5.4% in the third quarter. LPL Financial LLC now owns 168,479 shares of the company’s stock valued at $18,079,000 after purchasing an additional 8,573 shares during the last quarter. Capital World Investors grew its position in shares of Eli Lilly And Co by 177.6% in the third quarter. Capital World Investors now owns 1,013,300 shares of the company’s stock valued at $108,737,000 after purchasing an additional 648,300 shares during the last quarter. Veritable L.P. grew its position in shares of Eli Lilly And Co by 3.3% in the third quarter. Veritable L.P. now owns 30,953 shares of the company’s stock valued at $3,322,000 after purchasing an additional 1,002 shares during the last quarter. Finally, Caxton Associates LP acquired a new position in shares of Eli Lilly And Co in the third quarter valued at approximately $250,000. Institutional investors own 79.36% of the company’s stock.

LLY has been the topic of several research reports. Barclays reaffirmed a “buy” rating and issued a $130.00 target price on shares of Eli Lilly And Co in a research report on Sunday, January 20th. UBS Group assumed coverage on Eli Lilly And Co in a research report on Wednesday, January 23rd. They set a “buy” rating and a $131.00 price target on the stock. Cantor Fitzgerald reissued a “buy” rating on shares of Eli Lilly And Co in a research report on Monday, February 4th. Citigroup set a $124.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a research report on Tuesday, February 26th. Finally, JPMorgan Chase & Co. assumed coverage on Eli Lilly And Co in a research report on Tuesday, March 12th. They set an “overweight” rating and a $140.00 price target on the stock. Ten equities research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. Eli Lilly And Co currently has a consensus rating of “Buy” and a consensus price target of $118.83.

In other news, SVP Enrique A. Conterno sold 25,000 shares of the stock in a transaction on Friday, February 15th. The stock was sold at an average price of $121.00, for a total value of $3,025,000.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Alfonso G. Zulueta sold 10,000 shares of the stock in a transaction on Friday, April 12th. The shares were sold at an average price of $124.65, for a total value of $1,246,500.00. Following the completion of the transaction, the senior vice president now owns 57,806 shares of the company’s stock, valued at $7,205,517.90. The disclosure for this sale can be found here. Insiders sold a total of 863,382 shares of company stock valued at $108,785,182 over the last quarter. 0.11% of the stock is owned by corporate insiders.

NYSE LLY traded down $1.55 on Friday, hitting $116.91. 5,695,035 shares of the company’s stock were exchanged, compared to its average volume of 13,865,593. The company has a debt-to-equity ratio of 1.07, a current ratio of 1.73 and a quick ratio of 1.38. Eli Lilly And Co has a 52 week low of $77.09 and a 52 week high of $132.13. The stock has a market capitalization of $121.23 billion, a PE ratio of 21.06, a PEG ratio of 2.22 and a beta of 0.27.

Eli Lilly And Co (NYSE:LLY) last announced its quarterly earnings results on Tuesday, April 30th. The company reported $1.33 EPS for the quarter, beating the Zacks’ consensus estimate of $1.32 by $0.01. Eli Lilly And Co had a return on equity of 45.44% and a net margin of 26.13%. The company had revenue of $5.09 billion during the quarter, compared to analysts’ expectations of $5.12 billion. During the same period in the prior year, the company earned $1.31 EPS. Eli Lilly And Co’s revenue was up 2.6% compared to the same quarter last year. As a group, sell-side analysts expect that Eli Lilly And Co will post 5.67 earnings per share for the current year.

TRADEMARK VIOLATION NOTICE: “Eli Lilly And Co (NYSE:LLY) Holdings Lowered by Country Club Trust Company n.a.” was first published by Baseball Daily News and is owned by of Baseball Daily News. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.baseballdailydigest.com/news/2019/05/04/eli-lilly-and-co-lly-shares-sold-by-country-club-trust-company-n-a.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Price to Earnings Ratio (PE)

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.